ALT Altimmune Inc

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in the following investor conferences:

  • Guggenheim Inaugural Healthcare Innovation Conference (Boston, MA)

    Monday, November 11, 2024

    Fireside Chat at 11:30 a.m. Eastern Time
  • UBS Global Healthcare Conference (Rancho Palos Verdes, CA)

    Wednesday, November 13, 2024

    Available for 1x1 meetings

    Fireside Chat at 9:30 a.m. Pacific Time

The sessions will be webcast and can be accessed by visiting the section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Company Contact:

Vipin Garg

President and Chief Executive Officer

Phone: 240-654-1450

Media Contact:

Danielle Cantey

Inizio Evoke, Biotech

Phone: 619-826-4657

Investor Contacts:

Lee Roth

Burns McClellan

Phone: 646-382-3403

Julia Weilman

Burns McClellan

Phone: 646-732-4443

This press release was published by a CLEAR® Verified individual.



EN
06/11/2024

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in Upcoming Investor Conferences

Altimmune to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: Wells Fargo Healthcare Conference in Boston, MA Friday, September 5, 2025 One-on-one meetings only H.C. Wainwright Global Investment Conference in New York, NY Tuesday, September 9, 2025 Fireside chat at 8:30 a....

11h / 18m 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alco...

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disorder ...

August 19, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Second Quarter 2025 Financial Results and Business...

Altimmune Announces Second Quarter 2025 Financial Results and Business Update Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments...

August 12, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Board of Directors Appoints Jerry Durso as Chairman

Altimmune Board of Directors Appoints Jerry Durso as Chairman Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025. Mr. Durso s...

August 11, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Report Second Quarter 2025 Financial Results and Provide ...

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at . Participants who would like to join t...

August 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch